Compare Lowe`s Companies Inc (LOW) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lowe`s Companies Inc vs TransMedics Group Inc — how do they compare? Lowe`s Companies Inc trades at $185.98 (market cap $105.96B), while TransMedics Group Inc trades at $78.15 (market cap $2.74B). The key difference: Lowe`s Companies Inc is far larger — about 38.7× TransMedics Group Inc's market cap, and Lowe`s Companies Inc pays a 2.65% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Lowe`s Companies Inc for 98 Days and TransMedics Group Inc for 24 Days on average.
| LOW | TMDX | |
|---|---|---|
Market Cap | $105.96B | $2.74B |
Volume | 4,039,547 | 949,331 |
Sector | Consumer Cyclical | Health |
52-Week High | $287.39 | $150.42 |
52-Week Low | $179.50 | $61.99 |
Typical Hold Time | 98 Days | 24 Days |
Enterprise Value | $144.81B | $3.13B |
Dividend Yield | 2.65% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lowe's (LOW) trades at $185.27, up 2.05% today, but faces a bearish technical signal with key resistance at $191. The company reported Q2 2026 EPS of $4.40, beating estimates, yet revenue has declined from $96.2B in 2022 to $83.7B in 2025. Analysts maintain a strong buy consensus with a $244.09 price target, citing value despite industry headwinds. Recent news highlights drone delivery innovation with DoorDash and Alphabet's Wing, aiming to enhance customer convenience.
LOW presents a value opportunity with a P/E of 15.96 and bullish analyst sentiment, but risks include a challenging housing market and declining revenue trends. The stock's upside hinges on execution of new initiatives and economic recovery in home improvement spending, with near-term volatility expected amid macroeconomic uncertainty.
TransMedics Group (TMDX) trades at $78.17, down 3.58% on the day, with a bearish technical signal and mixed earnings history. The company reported strong 2025 results with $605.49M revenue and $190.29M net income, but 2026 projections show margin compression. Recent news highlights insider buying and leadership changes alongside legal investigations into fiduciary duties, creating a complex sentiment backdrop.
The stock offers growth potential with a consensus price target of $99.75, but faces risks from earnings misses, margin pressure, and ongoing legal scrutiny. Analyst consensus remains bullish with 69% buy ratings, yet investors must weigh robust profitability metrics against execution and regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lowe`s Companies Inc
Lowe's is the second-largest home improvement retailer in the world, operating 1,969 stores and servicing around 230 dealer-owned stores throughout the United States and Canada. The firm's stores offer products and services for home decorating, maintenance, repair, and remodeling, with maintenance and repair accounting for two thirds of products sold. Lowe's targets retail do-it-yourself (around 75% of sales) and do-it-for-me customers as well as commercial and professional business clients (around 25% of sales). We estimate Lowe's captures a low-double-digit share of the domestic home improvement market, based on U.S. Census data and management's estimates for market size.
Read more on LOW →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
